Bestaande gebruiker? Log in
Abonneren
Home
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Analisten vandaag
Meest aanbevolen aandelen
Minst aanbevolen aandelen
Aandelen met grootste potentieel
Insider trading
Insiders vandaag
Meest gekochte aandelen
Meest verkochte aandelen
Mijn Trivano
Mijn Trivano
Mijn selecties
Abonneren
Beurs vandaag
Koersen
Nieuws
Agenda
Analisten
Insider trading
Mijn Trivano
Registreren / inloggen
Beurs vandaag
Dynavax Technologies Corp.
Nieuws
Dynavax Technologies Corp.
DVAX
NAS
: DVAX
| ISIN: US2681582019
11/07/2025
10,58 USD
(-2,94%)
(-2,94%)
11/07/2025
Aandeel volgen
Aandeel gevolgd
Samenvatting
Nieuws
Insiders
Technische analyse
TA
Toon enkel gratis nieuws
12 mei 2025 ·
Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value
· Persbericht
10 mei 2025 ·
/C O R R E C T I O N -- Dynavax Technologies/
· Persbericht
7 mei 2025 ·
Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum
· Persbericht
6 mei 2025 ·
Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs
· Persbericht
1 mei 2025 ·
Dynavax Announces Nationwide Harris Poll Survey Results Finding Americans Underestimate the Serious Consequences of Hepatitis B and Vaccine Protection Benefits
· Persbericht
29 april 2025 ·
Dynavax Highlights Superior Board Leadership Overseeing Long-Term Value Creation Strategy
· Persbericht
22 april 2025 ·
Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025
· Persbericht
17 april 2025 ·
Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders
· Persbericht
3 april 2025 ·
Dynavax Files Preliminary Proxy Statement
· Persbericht
6 maart 2025 ·
Dynavax Announces Convertible Debt Refinancing and Common Stock Share Repurchase
· Persbericht
6 augustus 2024 ·
Dynavax Reports Second Quarter 2024 Financial Results and Provides Business Updates
· Persbericht
23 juli 2024 ·
Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
· Persbericht
27 juni 2024 ·
Dynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine Program
· Persbericht
28 mei 2024 ·
Dynavax to Present at Upcoming Investor Conferences
· Persbericht
14 mei 2024 ·
Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S.
· Persbericht
8 mei 2024 ·
Dynavax Reports First Quarter 2024 Financial Results and Provides Business Updates
· Persbericht
24 april 2024 ·
Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
· Persbericht
28 februari 2024 ·
Dynavax to Present at TD Cowen's 44th Annual Health Care Conference
· Persbericht
22 februari 2024 ·
Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance
· Persbericht
8 februari 2024 ·
Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024
· Persbericht
Aandeel volgen
Aandeel gevolgd
Mijn selecties
Voorbeeldselectie
Je selectie is nog leeg.
Voeg nu effecten toe